|Bid||7,404.00 x 0|
|Ask||7,404.00 x 0|
|Day's range||7,237.00 - 7,449.00|
|52-week range||6,736.00 - 10,120.00|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||41.86|
|Earnings date||30 Apr 2021|
|Forward dividend & yield||2.07 (2.80%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||78.83|
AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects. Brian Orelli: AstraZeneca reported a final data from its COVID-19 vaccine -- that it went from 79% efficacy at preventing symptomatic COVID-19 for the interim look and then at the final look it was 76%.
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
Assistant Professor of Emergency Medicine at Baylor College of Medicine, Dr. Sara Andrabi, joined Yahoo Finance to break down her thoughts on the possibility of needing annual COVID-19 booster shots to.